Transdermal fentanyl as a front-line approach to moderate-severe pain: A meta-analysis of randomized clinical trials

Tassinari Davide, Sartori Sergio, Tamburini Emiliano, Scarpi Emanuela, Tombesi Paola, Santelmo Carlotta, Maltoni Marco

Research output: Contribution to journalArticle

Abstract

Objective: The safety of transdermal fentanyl (TF) in comparison with slow-release oral morphine (SROM) in moderate-severe pain was assessed. Design: A systematic review of the literature was performed to identify all randomized trials comparing TF and SROM in moderate-severe pain. Overall safety was the primary end point. Trials enrolling both cancer and non-cancer patients were included in the analysis. Heterogeneity was assessed using the Mantel-Haenszel test; a random effects model was used for the pooled analysis. Cumulative and distinctive analyses for cancer and non-cancer pain were performed whenever the outcome was reported in at least two trials. Results: Five trials met the inclusion criteria. A significant advantage of TF was documented for constipation, laxative use, and urinary retention. TF was preferred by cancer and non-cancer patients. A difference in favour of SROM was documented for nausea, diarrhea, and sweating in cancer and non-cancer patients. No differences were observed for the other items considered. Conclusions: TF and SROM seem to have a different side effects profile, and TF seems to be preferred by patients. The hierarchical approach traditionally recommended by the main scientific societies (oral morphine and then TF) could be replaced by a front-line approach based on patients' characteristics and needs.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalJournal of Palliative Care
Volume25
Issue number3
Publication statusPublished - Sep 2009

Fingerprint

Fentanyl
Meta-Analysis
Randomized Controlled Trials
Morphine
Pain
Neoplasms
Safety
Laxatives
Sweating
Urinary Retention
Constipation
Nausea
Diarrhea

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transdermal fentanyl as a front-line approach to moderate-severe pain : A meta-analysis of randomized clinical trials. / Davide, Tassinari; Sergio, Sartori; Emiliano, Tamburini; Emanuela, Scarpi; Paola, Tombesi; Carlotta, Santelmo; Marco, Maltoni.

In: Journal of Palliative Care, Vol. 25, No. 3, 09.2009, p. 172-180.

Research output: Contribution to journalArticle

Davide, Tassinari ; Sergio, Sartori ; Emiliano, Tamburini ; Emanuela, Scarpi ; Paola, Tombesi ; Carlotta, Santelmo ; Marco, Maltoni. / Transdermal fentanyl as a front-line approach to moderate-severe pain : A meta-analysis of randomized clinical trials. In: Journal of Palliative Care. 2009 ; Vol. 25, No. 3. pp. 172-180.
@article{62e1cbfa97aa46e196e06c65d3d51f5a,
title = "Transdermal fentanyl as a front-line approach to moderate-severe pain: A meta-analysis of randomized clinical trials",
abstract = "Objective: The safety of transdermal fentanyl (TF) in comparison with slow-release oral morphine (SROM) in moderate-severe pain was assessed. Design: A systematic review of the literature was performed to identify all randomized trials comparing TF and SROM in moderate-severe pain. Overall safety was the primary end point. Trials enrolling both cancer and non-cancer patients were included in the analysis. Heterogeneity was assessed using the Mantel-Haenszel test; a random effects model was used for the pooled analysis. Cumulative and distinctive analyses for cancer and non-cancer pain were performed whenever the outcome was reported in at least two trials. Results: Five trials met the inclusion criteria. A significant advantage of TF was documented for constipation, laxative use, and urinary retention. TF was preferred by cancer and non-cancer patients. A difference in favour of SROM was documented for nausea, diarrhea, and sweating in cancer and non-cancer patients. No differences were observed for the other items considered. Conclusions: TF and SROM seem to have a different side effects profile, and TF seems to be preferred by patients. The hierarchical approach traditionally recommended by the main scientific societies (oral morphine and then TF) could be replaced by a front-line approach based on patients' characteristics and needs.",
author = "Tassinari Davide and Sartori Sergio and Tamburini Emiliano and Scarpi Emanuela and Tombesi Paola and Santelmo Carlotta and Maltoni Marco",
year = "2009",
month = "9",
language = "English",
volume = "25",
pages = "172--180",
journal = "Journal of Palliative Care",
issn = "0825-8597",
publisher = "Institut Universitaire de Geriatrie de Montreal",
number = "3",

}

TY - JOUR

T1 - Transdermal fentanyl as a front-line approach to moderate-severe pain

T2 - A meta-analysis of randomized clinical trials

AU - Davide, Tassinari

AU - Sergio, Sartori

AU - Emiliano, Tamburini

AU - Emanuela, Scarpi

AU - Paola, Tombesi

AU - Carlotta, Santelmo

AU - Marco, Maltoni

PY - 2009/9

Y1 - 2009/9

N2 - Objective: The safety of transdermal fentanyl (TF) in comparison with slow-release oral morphine (SROM) in moderate-severe pain was assessed. Design: A systematic review of the literature was performed to identify all randomized trials comparing TF and SROM in moderate-severe pain. Overall safety was the primary end point. Trials enrolling both cancer and non-cancer patients were included in the analysis. Heterogeneity was assessed using the Mantel-Haenszel test; a random effects model was used for the pooled analysis. Cumulative and distinctive analyses for cancer and non-cancer pain were performed whenever the outcome was reported in at least two trials. Results: Five trials met the inclusion criteria. A significant advantage of TF was documented for constipation, laxative use, and urinary retention. TF was preferred by cancer and non-cancer patients. A difference in favour of SROM was documented for nausea, diarrhea, and sweating in cancer and non-cancer patients. No differences were observed for the other items considered. Conclusions: TF and SROM seem to have a different side effects profile, and TF seems to be preferred by patients. The hierarchical approach traditionally recommended by the main scientific societies (oral morphine and then TF) could be replaced by a front-line approach based on patients' characteristics and needs.

AB - Objective: The safety of transdermal fentanyl (TF) in comparison with slow-release oral morphine (SROM) in moderate-severe pain was assessed. Design: A systematic review of the literature was performed to identify all randomized trials comparing TF and SROM in moderate-severe pain. Overall safety was the primary end point. Trials enrolling both cancer and non-cancer patients were included in the analysis. Heterogeneity was assessed using the Mantel-Haenszel test; a random effects model was used for the pooled analysis. Cumulative and distinctive analyses for cancer and non-cancer pain were performed whenever the outcome was reported in at least two trials. Results: Five trials met the inclusion criteria. A significant advantage of TF was documented for constipation, laxative use, and urinary retention. TF was preferred by cancer and non-cancer patients. A difference in favour of SROM was documented for nausea, diarrhea, and sweating in cancer and non-cancer patients. No differences were observed for the other items considered. Conclusions: TF and SROM seem to have a different side effects profile, and TF seems to be preferred by patients. The hierarchical approach traditionally recommended by the main scientific societies (oral morphine and then TF) could be replaced by a front-line approach based on patients' characteristics and needs.

UR - http://www.scopus.com/inward/record.url?scp=70349706106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349706106&partnerID=8YFLogxK

M3 - Article

C2 - 19824278

AN - SCOPUS:70349706106

VL - 25

SP - 172

EP - 180

JO - Journal of Palliative Care

JF - Journal of Palliative Care

SN - 0825-8597

IS - 3

ER -